Page 2 - Thomask Equels News Today

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 -- AIM ImmunoTech Inc.   today announced the...

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is...

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...

OCALA - AIM ImmunoTech Inc. today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIMs Ampligen with AstraZenecas...

OCALA - AIM ImmunoTech Inc. today announced that enrollment is open at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIMs Ampligen with AstraZenecas anti-PD-L1 immune...

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,...

AIM ImmunoTech Inc. today announced that shareholders have elected all four of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the...

Court Finds Activist Group “Flouted” AIM’s Bylaws by Failing to Provide Required Information AIM Will Reconvene Annual Meeting Today and then Adjourn Until January 5th Any Proxies Submitted...

OCALA, Fla.--(BUSINESS WIRE)--Dec 29, 2023--

Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief...